Hello, everyone, and how are you today? We are doing just fine, thank you, now that another wintry storm has come and gone. A warm sun is now enveloping the Pharmalot campus, where the short person is leaving for the local schoolhouse and the officials mascots are enjoying diving about in the snow and slush. As for us, we are embarking on our usual daily journey of foraging for interesting items. And so, it is time to get cracking. Hope your day goes well and do drop us a line when something interesting develops …

Biosimilar versions of Roche’s (RHHBY) Rituxan blood cancer treatment have taken 80 percent of the U.K. market since launching last year, saving the health care system $113 million a year, Reuters writes. The rapid adoption of two biosimilars from Celltrion and Novartis has been accompanied by discounts of 50 percent to 60 percent as the U.K’s National Health Service has used bidding to bring down costs. The NHS has estimated that biosimilars could save it up to $420 million a year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that the last time Pfizer sold their Consumer Division, it was a great deal for J&J (the subsequent issues at Fort Washington not withstanding). Now it appears they will improve the lot of GSK. It seems Pfizer’s role is to enrich it’s competition – save the collateral damage to TEVA via Allergan, but “that’s just a coincidence.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy